局部矿物粉单药治疗活动性消化性溃疡出血
这项前瞻性、多中心、单臂研究评估Hemospray止血粉单药治疗Forrest Ia或Ib级消化性溃疡出血的安全性和有效性。Hemospray成功给药率98.5%(66/67),内镜下止血率90.9%(60/66),总体止血率97.0%(64/66),再出血率13.3%(8/60),Forrest Ia溃疡早期再出血率显著高于Forrest Ib溃疡。结论认为Hemospray是活动性消化性溃疡出血的有效初始治疗,但需注意监测再出血。
要点
- Hemospray单药治疗活动性消化性溃疡出血总体止血率97.0%(64/66)。
- 再出血率13.3%(8/60),Forrest Ia溃疡早期再出血率显著高于Forrest Ib溃疡。
- 研究期间发生2例穿孔和2例患者死亡,但均未归因于Hemospray使用。
核心结论
- Hemospray是活动性消化性溃疡出血的有效初始治疗,但应注意监测再出血。
研究设计与样本
- 前瞻性、多中心、单臂研究,纳入Forrest Ia或Ib级消化性溃疡患者,以Hemospray作为首选内镜治疗。
主要发现
- Hemospray成功给药率98.5%(66/67)。
- 内镜下止血率90.9%(60/66)为单用Hemospray,另4例联合其他方法后止血,总体止血率97.0%(64/66)。
- 再出血率13.3%(8/60),其中72小时内5例,72小时至30天3例。
- 研究期间发生2例穿孔和2例患者死亡,但均未归因于Hemospray使用。
- Forrest Ia溃疡患者的早期再出血率显著高于Forrest Ib溃疡患者。
关键数值与推荐
- Forrest Ia或Ib级消化性溃疡出血患者接受Hemospray作为首选内镜治疗。
临床怎么用
- 原文结论认为Hemospray是活动性消化性溃疡出血的有效初始治疗,但应注意监测再出血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The aim of this study was to evaluate the safety and effectiveness of Hemospray (Cook Medical, Winston-Salem, NC, USA), a hemostatic powder, as monotherapy for active peptic ulcer bleeding. METHODS: In this prospective, multicenter, single-arm study, patients with Forrest Ia or Ib peptic ulcers underwent endoscopic application of Hemospray as treatment of first intent. Effectiveness endpoints were successful hemostasis at the end of the index endoscopy, recurrent bleeding within 72 hours and from 72 hours to 30 days, adverse events requiring reintervention or resulting in morbidity or mortality, and 30-day mortality. RESULTS: Hemospray was successfully administered in 98.5% of patients (66/67). Hemostasis was achieved at the index endoscopy in 90.9% of patients (60/66) with Hemospray alone and in an additional 4 patients treated with additional modalities, yielding an overall hemostasis rate of 97.0% (64/66). Rebleeding occurred in 13.3% of patients (8/60), 5 within 72 hours and 3 between 72 hours and 30 days. Two cases of perforation and 2 patient deaths occurred during the study, but none of these cases or any other adverse events were attributed to the use of Hemospray. The rate of early rebleeding was significantly higher in patients with Forrest Ia ulcers compared with patients with Forrest Ib ulcers. Higher rates of early bleeding in patients with Forrest Ia ulcers is consistent with results from studies where Hemospray was used as rescue after failure of conventional methods. CONCLUSIONS: Hemospray is an effective initial treatment for patients with active peptic ulcer bleeding, but care should be taken to monitor for recurrent bleeding. (Clinical trial registration number: NCT01306864.).
引用
- Sung JJY, Moreea S, Dhaliwal H, et al. Use of topical mineral powder as monotherapy for treatment of active peptic ulcer bleeding. Gastrointest Endosc. 2022. PMID: 35124074. doi:10.1016/j.gie.2022.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。